Donald Paul Quick MD

Hematologic Oncology

Physician

4101 22nd PlLubbock, TX 79410
Phone+1 806-725-8000
Fax+1 806-723-6532

Dr. Quick is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Quick's full profile Already have an account?

Summary

Donald Quick, MD, is a renowned Oncologist with a subspecialty in Hematologic Oncology located in Lubbock, TX. He completed his medical education at Baylor College of Medicine and Fellowship in Hematology and Medical Oncology at Ohio State University Hospital. He has considerable clinical experience in conditions such as acute and chronic leukemias, lymphomas, multiple myeloma, myelodysplastic syndrome, coagulopathies, and benign hematology. Dr. Quick has been published in several esteemed medical journals and participated in multiple clinical trials. He received the Meaningful Use Stage 1 Certification from the Centers for Medicare & Medicaid Services in 2011.

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1985 - 1988
Baylor Scott & White Medical Center - Baylor College of Medicine (Temple)Residency, Internal Medicine, 1982 - 1985
Baylor College of MedicineClass of 1982

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NM State Medical License 2005 - 2027
TX State Medical License 1983 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2012-2017
CMS Meaningful Use Stage 2 Certification Allscripts Enterprise EHR, Allscripts, 2012-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2017

Clinical Trials

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
COMPLETED
PHASE3
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
COMPLETED
PHASE3
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
TERMINATED
PHASE1, PHASE2

Publications & Presentations

PubMed

Metachronous metastasis of renal cell carcinoma to the contralateral ureter 8 years after nephrectomy presenting as hydronephrosis.
Kolos K Nagy, Caroline J Cushman, Jason R Jesudass, Seshadri D Thirumala, Brian E Nicholson
Urology Case Reports. 2026-05-01
10 citations
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.
Nizar J Bahlis, Christy Samaras, Donna Reece, Michael Sebag, Jeffrey Matous
Clinical Lymphoma, Myeloma & Leukemia. 2024-12-01
5 citations
Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.
Alexis C Boulter, Barry J Maurer, Meredith Pogue, Min H Kang, Hwangeui Cho
Cancer Chemotherapy and Pharmacology. 2023-08-01

Abstracts/Posters

Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
Donald P. Quick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials
Donald P. Quick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab
Donald P. Quick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018